Dr. Agarwal on latest COSMIC-021 data for atezolizumab/cabozantinib in mCRPC

Neeraj Agarwal, MD, discusses updated data from the phase 1b COSMIC-021 trial, which showed that the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer (mCRPC).

Agarwal, a professor of Medicine at the Huntsman Cancer Institute, University of Utah, and an investigator on the COSMIC-021 trial, also discusses the ongoing phase 3 randomized, open-label, CONTACT-02 study (NCT04446117), which is exploring cabozantinib plus atezolizumab versus second novel hormone therapy (NHT; abiraterone acetate, enzalutamide, etc) in patients with mCRPC who previously received 1 NHT to treat metastatic castration-sensitive prostate cancer, non-metastatic CRPC, or mCRPC.